68镓前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与多参数磁共振成像及根治性前列腺切除标本病理对比检测和定位原发性前列腺癌
回顾性分析四个中心2015至2018年205例根治性前列腺切除术前接受68Ga-PSMA PET/CT与mpMRI的原发性前列腺癌患者,以根治标本病理为参照。68Ga-PSMA PET/CT与mpMRI在检出任何肿瘤(94% vs 95%,P>0.9)、定位所有索引肿瘤(91% vs 89%,P=0.47)、临床显著索引肿瘤(96% vs 91%,P=0.15)及移行带肿瘤(85% vs 80%,P>0.9)上均无显著差异。
要点
- 68Ga-PSMA PET/CT与mpMRI检出任何肿瘤的准确率分别为94%与95%,无显著差异(P>0.9)。
- 定位所有索引肿瘤的准确率68Ga-PSMA PET/CT为91%,mpMRI为89%,无显著差异(P=0.47)。
- 定位临床显著索引肿瘤68Ga-PSMA PET/CT为96% vs mpMRI 91%,无显著差异(P=0.15)。
核心结论
- 68Ga-PSMA PET/CT与mpMRI在检出或定位原发性前列腺癌方面无显著差异。
- 需要进一步的前瞻性研究评估PET/MRI联合模型以减少任一 modality 遗漏的肿瘤。
研究设计与样本
- 回顾性研究,纳入四个中心2015年至2018年间根治性前列腺切除术前接受68Ga-PSMA PET/CT和mpMRI的原发性前列腺癌男性。
- 排除因复发疾病或非手术治疗前接受影像检查的患者。
- 以根治标本病理上国际泌尿病理学会分级分组(GG)最高的病变定义为病理索引肿瘤。
- 临床显著疾病定义为GG 3-5。
- 使用描述性统计和Mann-Whitney U检验比较检出、遗漏和定位肿瘤的人口学和病理特征,使用McNemar检验比较两种影像模态的检出和定位率。
主要发现
- 共纳入205名男性,其中133名患有临床显著疾病。
- 68Ga-PSMA PET/CT与mpMRI检出任何肿瘤的比率分别为94%与95%,无显著差异(P>0.9)。
- 68Ga-PSMA PET/CT与mpMRI定位所有索引肿瘤的比率分别为91%与89%,无显著差异(P=0.47)。
- 68Ga-PSMA PET/CT与mpMRI定位临床显著索引肿瘤的比率分别为96%与91%,无显著差异(P=0.15)。
- 68Ga-PSMA PET/CT与mpMRI定位移行带肿瘤的比率分别为85%与80%,无显著差异(P>0.9)。
关键数值与推荐
- 肿瘤检出定义为影像病变在任何成像平面上与根治标本肿瘤对应。
- 肿瘤定位定义为影像病变在矢状面、轴面和冠状面上均与根治标本索引肿瘤匹配。
- 临床显著疾病定义为GG 3-5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括回顾性研究设计。
- 局限性包括影像和病理的非中心化审阅。
- 需要进一步的前瞻性研究评估PET/MRI联合模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the accuracy of 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography (68 Ga-PSMA PET/CT) with multiparametric MRI (mpMRI) in detecting and localising primary prostate cancer when compared with radical prostatectomy (RP) specimen pathology. PATIENTS AND METHODS: Retrospective review of men who underwent 68 Ga-PSMA PET/CT and mpMRI for primary prostate cancer before RP across four centres between 2015 and 2018. Patients undergoing imaging for recurrent disease or before non-surgical treatment were excluded. We defined pathological index tumour as the lesion with highest International Society of Urological Pathology Grade Group (GG) on RP specimen pathology. Our primary outcomes were rates of accurate detection and localisation of RP specimen pathology index tumour using 68 Ga-PSMA PET/CT or mpMRI. We defined tumour detection as imaging lesion corresponding with RP specimen tumour on any imaging plane, and localisation as imaging lesion matching RP specimen index tumour in all sagittal, axial, and coronal planes. Secondary outcomes included localisation of clinically significant and transition zone (TZ) index tumours. We defined clinically significant disease as GG 3-5. We used descriptive statistics and the Mann-Whitney U-test to define and compare demographic and pathological characteristics between detected, missed and localised tumours using either imaging modality. We used the McNemar test to compare detection and localisation rates using 68 Ga-PSMA PET/CT and mpMRI. RESULTS: In all, 205 men were included in our analysis, including 133 with clinically significant disease. There was no significant difference between 68 Ga-PSMA PET/CT and mpMRI in the detection of any tumour (94% vs 95%, P > 0.9). There was also no significant difference between localisation of all index tumours (91% vs 89%, P = 0.47), clinically significant index tumours (96% vs 91%, P = 0.15) or TZ tumours (85% vs 80%, P > 0.9) using 68 Ga-PSMA PET/CT and mpMRI. Limitations include retrospective study design and non-central review of imaging and pathology. CONCLUSION: We found no significant difference in the detection or localisation of primary prostate cancer between 68 Ga-PSMA PET/CT and mpMRI. Further prospective studies are required to evaluate a combined PET/MRI model in minimising tumours missed by either modality.
引用
- Kalapara AA, Nzenza T, Pan HYC, et al. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int. 2020. PMID: 31260602. doi:10.1111/bju.14858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。